Ezobresib
Overview of the drug Ezobresib
| Ezobresib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ezobresib is a small molecule inhibitor that targets the bromodomain and extraterminal domain (BET) family of proteins. It is primarily investigated for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit]
Ezobresib functions by inhibiting the BET family of proteins, which includes BRD2, BRD3, BRD4, and BRDT. These proteins are involved in regulating gene expression by binding to acetylated lysines on histone tails, thereby influencing chromatin structure and function. By inhibiting these interactions, Ezobresib can disrupt the expression of genes that are critical for cancer cell growth and survival.
Pharmacology[edit]
Ezobresib is administered orally and has been shown to have a favorable pharmacokinetic profile. It is absorbed into the bloodstream and distributed throughout the body, where it exerts its effects on BET proteins. The drug is metabolized primarily in the liver and excreted through the kidneys.
Clinical Development[edit]
Ezobresib is currently undergoing clinical trials to evaluate its efficacy and safety in treating various malignancies, including hematological cancers and solid tumors. Early-phase trials have demonstrated promising results, with some patients experiencing significant tumor reduction.
Potential Side Effects[edit]
As with many cancer therapies, Ezobresib may cause side effects. Commonly reported adverse effects include fatigue, nausea, and decreased blood cell counts. More serious side effects can occur, and patients are monitored closely during treatment.
Research and Future Directions[edit]
Ongoing research is focused on understanding the full potential of Ezobresib in cancer therapy. Studies are exploring its use in combination with other anticancer agents to enhance therapeutic outcomes. Additionally, research is being conducted to identify biomarkers that can predict patient response to Ezobresib.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
